UNSPSC 51362508: Cloperidone hydrochloride

This classification denotes a sedative and hypnotic with the molecular formula C21H23ClN4O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 17682058OP, chemically known as 2,4(1h,3h)-quinazolinedione, 3-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-, monohydrochloride but more generally known as cloperidone hydrochloride, which bears US NIH Compound Identifier 10674. Most nations, for tariff and trade purposes, schedule cloperidone hydrochloride under HS 29335995 and SITC 51576.

As of Q4 2014, CLOPERIDONE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Cloperidone hydrochloride bears US NLM identifiers UMLS ID C2825297 and NCI Concept Code C80665. SMILES: C1CCC2C(C1)C(=O)N(C(=O)[NH]2)CCCN3CCN(CC3)C4CCCC(C4)CL.CL.

UNSPSC 51362508 Cloperidone hydrochloride is a Commodity code that nominally names a single antipsychotic pharmaceutical product, but the recent state and local opportunities tagged under it reflect the broader pharmaceutical procurement activity state and local health agencies are conducting — specifically generic medications, naloxone, and over-the-counter products sourced through wholesaler networks and direct-to-manufacturer channels. State and local buying here spans county health departments, state health and human services commissions, and multistate cooperative purchasing alliances procuring on behalf of their member agencies and facilities. The actual work involves competitive bidding for pharmaceutical supply contracts with specific dosage forms, packaging, compliance certifications (cGMP, DSCSA, FDA), and delivery to public health locations; pricing models range from fixed-price to net-price to WAC-minus structures. Vendors must maintain relationships with authorized pharmaceutical wholesalers, carry substantial insurance coverage, and comply with federal procurement requirements including E-Verify and drug-free workplace certification.

Recent activity shows Seminole County, Florida issuing an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building; the Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota, Oregon, and other member jurisdictions through authorized wholesalers AmerisourceBergen, Cardinal Health, and Morris & Dickson. Activity spans Florida, Texas, and the upper Midwest, with multistate cooperative purchasing showing the broadest geographic reach. Evaluation criteria in open RFPs emphasize price competitiveness (often 75 percent weight), compliance with supply-chain security regulations, EDI capability, and administrative fee structures (typically 3 percent); contract terms run two years with renewal options.